Highlights Newsletter 4
This newsletter presents you the following key sessions:
2. Nivolumab for pre-treated malignant pleural mesothelioma patients: real world evidence
4. Platinum-based chemoradiotherapy plus pembrolizumab for unresectable, stage III NSCLC
5. Neoadjuvant atezolizumab for early-stage NSCLC: encouraging results from the phase II LCMC3 trial